Remove 2022 Remove Compounding Remove Labelling
article thumbnail

Europe’s pharmaceutical packaging market to value over $35bn by 2028

European Pharmaceutical Review

Europe’s pharmaceutical packaging and labelling market is projected to reach $35.78 billion in 2022, the pharmaceutical packaging and labelling market in Europe is expected to expand at a compound annual growth rate (CAGR) of 4.78 percent in 2022. percent in 2022. Having been valued at $27.04

Packaging 118
article thumbnail

Your favourite nutraceuticals can be toxic: Discovered by Nutrify Genie

Express Pharma

These naturally occurring compounds offer significant benefits such as antioxidants, anti-inflammatory properties, and antiproliferative effects. Several studies have reported beneficial or protective effects of compounds such as resveratrol, quercetin, EGCG, and astaxanthin against various diseases.

Labelling 122
Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trending Sources

article thumbnail

Extemporaneous Compounding

RX Note

Introduction In 2018, the Ministry of Health Malaysia published the Good Compounding Practice as a guidance for compounding practices. Malaysia became the 26th member of PIC/S in January 2022. Glass mortars are used for liquids , such as suspensions and solutions, and for mixing compounds that are oily or can stain.

article thumbnail

Myasthenia gravis market to generate sales of $6.7 bn across 7MM by 2032: GlobalData

Express Pharma

The market for myasthenia gravis (MG), an autoimmune and neuromuscular disease characterised by muscle weakness and fatigue, is set to experience a compound annual growth rate (CARG) of 8.3 per cent across the seven major markets (7MM*) from $3 billion in 2022 to $6.7 billion in 2032, forecasts GlobalData.

Labelling 105
article thumbnail

First subject dosed in psilocybin trial for rare headache disorder

pharmaphorum

The phase 1b trial should generate results in early 2022 and is something if a departure for the use of psychedelic medicines, which are typically being tested at higher doses in carefully controlled environments and alongside psychological therapy for indications like depression and post-traumatic stress disorder (PTSD).

Labelling 105
article thumbnail

EU antibiotic shortages being monitored by MSSG

European Pharmaceutical Review

Monitoring medicine shortages Since November 2022, MSSG and its working party, the Medicines Shortages Single Point of Contact (SPOC) working party, have been closely monitoring the EU antibiotic shortages. In addition, MSSG supports temporary national measures such as unit dose dispensing and compounding.

article thumbnail

Pharma in Brief: The 2022 Year in Review

Pharma in Brief

Does 2022 already seem like a blur? The Pharma in Brief team is here for you with a summary of some of 2022’s most significant legal and regulatory developments in the Canadian pharmaceutical space. This left the PMPRB11 amendment, the validity of which was upheld by the FCA in December 2022 (see here ).